Video Experimental Relacionado

Updated: Sep 9, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

GLP-1RA y reducción de la mortalidad, los riesgos cardiovasculares y psiquiátricos en la psoriasis: un estudio de

Henning Olbrich¹, Khalaf Kridin^2,3,4, Henner Zirpel⁵

¹Department of Dermatology, Allergy, and Venerology, University of Lübeck, Lübeck, Germany.

The British journal of dermatology

|September 2, 2025

Resumen

Los agonistas de los receptores de péptido 1 similares al glucagón (GLP-1RA) redujeron significativamente la mortalidad y los riesgos cardiovasculares en pacientes con psoriasis con obesidad o diabetes. Este tratamiento seguro también redujo los riesgos de comorbilidad psiquiátrica, con mayores beneficios observados en pacientes con psoriasis.

Área de la Ciencia:

Dermatología
Cardiología
Endocrinología

Sus antecedentes:

La psoriasis está relacionada con problemas cardiovasculares y metabólicos graves.
Los agonistas de los receptores de péptido 1 similares al glucagón (GLP-1RA) se usan para la obesidad y la diabetes y pueden beneficiar a los pacientes con psoriasis.

Objetivo del estudio:

Evaluar los efectos del GLP- 1RA en la mortalidad, los resultados cardiovasculares, inflamatorios y psiquiátricos en pacientes con psoriasis.
Evaluar las reacciones adversas asociadas con GLP- 1RA en esta población.

Principales métodos:

Estudio de cohorte retrospectivo basado en la población utilizando datos de TriNetX de los Estados Unidos.
Compararon a 3.048 pacientes con psoriasis tratados con GLP- 1RA con los tratados con otros tratamientos después de hacer coincidir la puntuación de propensión.
Se analizaron los resultados cardiometabólicos, psiquiátricos, autoinmunes, la mortalidad y los eventos adversos; validados en cohortes sin psoriasis.

Principales resultados:

El uso de GLP- 1RA se relacionó con una mortalidad por cualquier causa significativamente menor (HR 0. 219) y eventos cardíacos adversos mayores (MACE) (HR 0. 561) en pacientes con psoriasis.
Se observaron riesgos reducidos de abuso de alcohol y sustancias.
No hubo aumento en los eventos adversos típicos de los fármacos; las reducciones de riesgo fueron mayores que en las cohortes sin psoriasis.

Conclusiones:

El tratamiento con GLP- 1RA es seguro para pacientes con psoriasis con obesidad o diabetes.
GLP- 1RA reduce significativamente los riesgos de comorbilidad cardiovascular y psiquiátrica y la mortalidad en este grupo.
Los médicos deben considerar el GLP- 1RA en pacientes con psoriasis con obesidad comórbida o diabetes.

Más Videos Relacionados

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Videos de Conceptos Relacionados

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

GPCRs Regulate Adenylyl Cylase Activity

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...